Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

Table 3 Univariate and multivariate analyses for progression-free survival

	Univariate analysis
Factors	HR (95% CI)	p value
Age (years)
<50 (vs. ≥50)	1.23 (0.82–1.84)	0.322
Tumor origin
Bone (vs. soft tissue)	1.05 (0.65–1.69)	0.843
Primary site		0.648
Trunk (vs. extremities)	1.20 (0.67–2.15)	0.542
Retroperitoneum (vs. extremities)	1.02 (0.56–1.85)	0.957
Visceral (vs. extremities)	1.48 (0.78–2.83)	0.231
Histological subtype		0.008
UPS (vs. leiomyosarcoma)	1.20 (0.61–2.35)	0.591
Others (vs. leiomyosarcoma)	2.01 (1.23–3.21)	0.004
Prior chemotherapy		0.028
Second-line (vs. first-line)	0.99 (0.55–1.78)	0.974
Third-or-greater line (vs. first-line)	1.74 (0.97–3.12)	0.064
Response to GD
SD/PD (vs. CR/PR)	2.05 (0.99–4.23)	0.053
	Multivariate analysis
Factors	HR (95% CI)	p value
Age (years)
≥50 (vs. <50)
Tumor origin
Bone (vs. soft tissue)
Primary site
Trunk (vs. extremities)
Retroperitoneum (vs. extremities)
Visceral (vs. extremities)
Histological subtype
UPS (vs. leiomyosarcoma)
Others (vs. leiomyosarcoma)
Prior chemotherapy		0.043
Second-line (vs. first-line)	1.02 (0.56–1.83)	0.974
Third-or-greater line (vs. first-line)	1.71 (0.95–3.07)	0.074
Response to GD
SD/PD (vs. CR/PR)

ISSN: 1477-7819